SE0002754D0 - New pharmaceutical combination formulation and method of treatment with the combination - Google Patents
New pharmaceutical combination formulation and method of treatment with the combinationInfo
- Publication number
- SE0002754D0 SE0002754D0 SE0002754A SE0002754A SE0002754D0 SE 0002754 D0 SE0002754 D0 SE 0002754D0 SE 0002754 A SE0002754 A SE 0002754A SE 0002754 A SE0002754 A SE 0002754A SE 0002754 D0 SE0002754 D0 SE 0002754D0
- Authority
- SE
- Sweden
- Prior art keywords
- combination
- treatment
- receptor
- new pharmaceutical
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Priority Applications (21)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002754A SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | New pharmaceutical combination formulation and method of treatment with the combination |
KR1020037000321A KR100845450B1 (ko) | 2000-07-21 | 2001-07-19 | 약학적 제형물로서의 세로토닌 아고니스트 (5에이치티2)및 안타고니스트 (5에이치티6) 의 새로운 조합 |
HU0301346A HUP0301346A3 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical composition and process for its preparation |
IL15405701A IL154057A0 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation |
EA200300183A EA006604B1 (ru) | 2000-07-21 | 2001-07-19 | Сочетание агониста (5-ht2) и антагониста (5-ht6) серотонина в качестве фармацевтической композиции |
BR0112661-0A BR0112661A (pt) | 2000-07-21 | 2001-07-19 | Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica |
AU2001282734A AU2001282734B2 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
AU8273401A AU8273401A (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
CNB018131549A CN1221254C (zh) | 2000-07-21 | 2001-07-19 | 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂 |
NZ523216A NZ523216A (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation |
EP01961472A EP1301476A1 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
MXPA03000548A MXPA03000548A (es) | 2000-07-21 | 2001-07-19 | Combinacion novedosa de agonista (5-ht2) y antagonistas (5-ht6) de serotonina como formulacion farmaceutica. |
PCT/SE2001/001651 WO2002008178A1 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
YU2603A YU2603A (sh) | 2000-07-21 | 2001-07-19 | Nova kombinacija (5ht2) agonista i (5ht6) antagonista serotonina kao farmaceutska kombinacija |
JP2002514087A JP2004504376A (ja) | 2000-07-21 | 2001-07-19 | 医薬製剤としてのセロトニンアゴニスト(5ht2)とアンタゴニスト(5ht6)の新規組み合わせ |
CA002411192A CA2411192A1 (en) | 2000-07-21 | 2001-07-19 | Combination of serotonin agonist (5ht2) and antagonist (5ht6)as a pharmaceutical formulation |
PL36030901A PL360309A1 (en) | 2000-07-21 | 2001-07-19 | New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
US09/908,801 US6818639B2 (en) | 2000-07-21 | 2001-07-20 | Pharmaceutical combination formulation and method of treatment with the combination |
ZA200210234A ZA200210234B (en) | 2000-07-21 | 2002-12-18 | New combination of serotonin agonist (5HT2) and antagonist (5HT6) as pharmaceutical formulation. |
NO20030304A NO20030304L (no) | 2000-07-21 | 2003-01-20 | Ny kombinasjon av serotoninagonist (5HT2) og antagonist (5HT6) som farmasoytisk formulering |
HK04100306A HK1057536A1 (en) | 2000-07-21 | 2004-01-15 | New combination of serotonin agonist (5ht2) and antagonist (5ht6) as pharmaceutical formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0002754A SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | New pharmaceutical combination formulation and method of treatment with the combination |
Publications (1)
Publication Number | Publication Date |
---|---|
SE0002754D0 true SE0002754D0 (sv) | 2000-07-21 |
Family
ID=20280577
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SE0002754A SE0002754D0 (sv) | 2000-07-21 | 2000-07-21 | New pharmaceutical combination formulation and method of treatment with the combination |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP1301476A1 (sv) |
JP (1) | JP2004504376A (sv) |
KR (1) | KR100845450B1 (sv) |
CN (1) | CN1221254C (sv) |
AU (2) | AU8273401A (sv) |
BR (1) | BR0112661A (sv) |
CA (1) | CA2411192A1 (sv) |
EA (1) | EA006604B1 (sv) |
HK (1) | HK1057536A1 (sv) |
HU (1) | HUP0301346A3 (sv) |
IL (1) | IL154057A0 (sv) |
MX (1) | MXPA03000548A (sv) |
NO (1) | NO20030304L (sv) |
NZ (1) | NZ523216A (sv) |
PL (1) | PL360309A1 (sv) |
SE (1) | SE0002754D0 (sv) |
WO (1) | WO2002008178A1 (sv) |
YU (1) | YU2603A (sv) |
ZA (1) | ZA200210234B (sv) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7034029B2 (en) | 2000-11-02 | 2006-04-25 | Wyeth | 1-aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands |
BR0115102B1 (pt) * | 2000-11-02 | 2013-11-26 | Compostos 1-aril- ou 1-alquilsulfonil-heterociclilbenzazóis e composição compreendendo os mesmos | |
CN1321110C (zh) * | 2001-06-15 | 2007-06-13 | 弗·哈夫曼-拉罗切有限公司 | 具有5-ht6受体亲和力的4-哌嗪基吲哚衍生物 |
DE60212841T2 (de) * | 2001-06-15 | 2007-06-21 | F. Hoffmann-La Roche Ag | 4 piperazinylindolderivate mit affinität zum 5-ht6-rezeptor |
US6825198B2 (en) | 2001-06-21 | 2004-11-30 | Pfizer Inc | 5-HT receptor ligands and uses thereof |
GB0202679D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Group Ltd | Novel compounds |
JP4455064B2 (ja) | 2002-03-27 | 2010-04-21 | グラクソ グループ リミテッド | キノリン誘導体および5−ht6リガンドとしてのその使用 |
CL2004000826A1 (es) * | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
EA009732B1 (ru) | 2003-07-22 | 2008-02-28 | Арена Фармасьютикалз, Инк. | Диарильные и арилгетероарильные производные мочевины в качестве модуляторов 5-ht-рецептора серотонина, пригодные для профилактики и лечения связанных с ним заболеваний |
WO2006022420A1 (ja) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
WO2007076875A2 (en) * | 2006-01-06 | 2007-07-12 | Aarhus Universitet | Compounds acting on the serotonin transporter |
JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
WO2007149728A2 (en) * | 2006-06-20 | 2007-12-27 | Alcon Research, Ltd. | Aryl and heteroaryl tetrahydrobenzazepine derivatives and their use for treating glaucoma |
DE602007012080D1 (de) * | 2007-08-01 | 2011-03-03 | Esteve Labor Dr | Kombination von mindestens zwei 5-HT6-Liganden |
EP2789338A3 (en) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Condensed pyridine derivate and use thereof |
WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
UA100192C2 (en) | 2008-11-11 | 2012-11-26 | УАЙТ ЭлЭлСи | 1-(arylsulfonyl)-4-(piperazin-1-yl)-1h-benzimidazoles as 5-hydroxytryptamine-6 ligands |
EA021079B1 (ru) | 2009-06-15 | 2015-03-31 | Такеда Фармасьютикал Компани Лимитед | Производные пиразинооксазепина |
WO2011071136A1 (ja) | 2009-12-11 | 2011-06-16 | アステラス製薬株式会社 | 線維筋痛症治療剤 |
EP4119141A1 (en) | 2015-06-12 | 2023-01-18 | Axovant Sciences GmbH | Nelotanserin for the prophylaxis and treatment of rem sleep behavior disorder |
BR112018000728A2 (pt) | 2015-07-15 | 2018-09-04 | Axovant Sciences Gmbh | resumo método para a profilaxia e/ou tratamento de alucinações visuais em um sujeito com necessidade do mesmo |
CN107628981B (zh) * | 2017-10-31 | 2019-07-30 | 威海市妇女儿童医院 | 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用 |
JPWO2019131902A1 (ja) | 2017-12-27 | 2020-12-10 | 武田薬品工業株式会社 | 腹圧性尿失禁および便失禁の治療薬 |
CN111269165A (zh) * | 2018-12-05 | 2020-06-12 | 中国科学院大连化学物理研究所 | 一种3-芳基磺酰基吲哚衍生物的合成方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DZ2376A1 (fr) * | 1996-12-19 | 2002-12-28 | Smithkline Beecham Plc | Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant. |
GB9803411D0 (en) * | 1998-02-18 | 1998-04-15 | Smithkline Beecham Plc | Novel compounds |
US6100291A (en) * | 1998-03-16 | 2000-08-08 | Allelix Biopharmaceuticals Inc. | Pyrrolidine-indole compounds having 5-HT6 affinity |
US6251893B1 (en) * | 1998-06-15 | 2001-06-26 | Nps Allelix Corp. | Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity |
GB9819035D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Res Ltd | Chemical compounds VII |
-
2000
- 2000-07-21 SE SE0002754A patent/SE0002754D0/sv unknown
-
2001
- 2001-07-19 CA CA002411192A patent/CA2411192A1/en not_active Abandoned
- 2001-07-19 KR KR1020037000321A patent/KR100845450B1/ko not_active IP Right Cessation
- 2001-07-19 JP JP2002514087A patent/JP2004504376A/ja not_active Withdrawn
- 2001-07-19 MX MXPA03000548A patent/MXPA03000548A/es active IP Right Grant
- 2001-07-19 AU AU8273401A patent/AU8273401A/xx active Pending
- 2001-07-19 PL PL36030901A patent/PL360309A1/xx not_active Application Discontinuation
- 2001-07-19 CN CNB018131549A patent/CN1221254C/zh not_active Expired - Fee Related
- 2001-07-19 WO PCT/SE2001/001651 patent/WO2002008178A1/en active IP Right Grant
- 2001-07-19 AU AU2001282734A patent/AU2001282734B2/en not_active Ceased
- 2001-07-19 HU HU0301346A patent/HUP0301346A3/hu unknown
- 2001-07-19 IL IL15405701A patent/IL154057A0/xx unknown
- 2001-07-19 EP EP01961472A patent/EP1301476A1/en not_active Withdrawn
- 2001-07-19 EA EA200300183A patent/EA006604B1/ru not_active IP Right Cessation
- 2001-07-19 YU YU2603A patent/YU2603A/sh unknown
- 2001-07-19 BR BR0112661-0A patent/BR0112661A/pt not_active IP Right Cessation
- 2001-07-19 NZ NZ523216A patent/NZ523216A/en not_active IP Right Cessation
-
2002
- 2002-12-18 ZA ZA200210234A patent/ZA200210234B/en unknown
-
2003
- 2003-01-20 NO NO20030304A patent/NO20030304L/no not_active Application Discontinuation
-
2004
- 2004-01-15 HK HK04100306A patent/HK1057536A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
PL360309A1 (en) | 2004-09-06 |
NO20030304L (no) | 2003-03-12 |
KR20030036599A (ko) | 2003-05-09 |
HK1057536A1 (en) | 2004-04-08 |
ZA200210234B (en) | 2004-03-18 |
HUP0301346A3 (en) | 2005-05-30 |
AU2001282734B2 (en) | 2006-10-12 |
EA006604B1 (ru) | 2006-02-24 |
AU8273401A (en) | 2002-02-05 |
CA2411192A1 (en) | 2002-01-31 |
CN1443162A (zh) | 2003-09-17 |
NZ523216A (en) | 2005-05-27 |
BR0112661A (pt) | 2003-06-24 |
EP1301476A1 (en) | 2003-04-16 |
IL154057A0 (en) | 2003-07-31 |
EA200300183A1 (ru) | 2003-08-28 |
MXPA03000548A (es) | 2004-04-05 |
NO20030304D0 (no) | 2003-01-20 |
HUP0301346A2 (hu) | 2003-08-28 |
JP2004504376A (ja) | 2004-02-12 |
CN1221254C (zh) | 2005-10-05 |
KR100845450B1 (ko) | 2008-07-10 |
YU2603A (sh) | 2006-05-25 |
WO2002008178A1 (en) | 2002-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SE0002754D0 (sv) | New pharmaceutical combination formulation and method of treatment with the combination | |
DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
CY1108201T1 (el) | Συσκευες διαδερματικης απελευθερωσης οπιοειδους που ειναι ανθεκτικες στην παραβιαση | |
ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
ATE401874T1 (de) | Verabreichung von capsaicinoiden | |
BR0015974A (pt) | Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto | |
AU2003268144A8 (en) | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist | |
HK1076379A1 (en) | Use of a composition comprising anti-vla-1 antibody for the preparation of a pharmaceutical composition for the treatment of pulmonary fibrosis | |
CY1118924T1 (el) | Μεθοδος για θεραπεια της πρωτοπαθους αϋπνιας | |
SE9900961D0 (sv) | Novel compounds | |
NO20024646D0 (no) | Kombinasjonsterapier med vaskul¶r-skadende aktivitet | |
EA200600817A1 (ru) | Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты) | |
SE9802208D0 (sv) | Novel compounds | |
BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
AR045783A1 (es) | Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide | |
WO2002034267A8 (de) | Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen | |
BR0201974A (pt) | Composição farmacêutica para tratamento de alterações do sono | |
BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
SE9802209D0 (sv) | Novel compounds | |
SE9902597D0 (sv) | New use | |
DK0799618T3 (da) | Anvendelse af alpha1-adrenoreceptor-antagonister i fremstillingen af et medikament til forebyggelsen og behandlingen af cancer | |
DE60204694D1 (de) | Kombinationstherapie zur behandlung von herzinsuffizienz | |
DE60004833D1 (de) | Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung | |
BR0005319A (pt) | Tratamento combinado para depressão e ansiedade | |
ATE260118T1 (de) | Zusammensetzungen von adenosin a1 agonisten mit 5ht1 agonisten |